Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have prostate cancer and have been on a type of hormone therapy called LHRH agonist therapy for more than 3 years
- People who are aged 70 years or older
- People whose general health and ability to carry out daily activities meets a certain level, known as an ECOG performance status of 2 or lower (confirm with trial site)
- People whose testosterone levels are below 20 ng/ml at the start of the trial
- People who have not previously received chemotherapy or a treatment called Lu-PSMA — although those with favorable survival predictions may still be considered (confirm with trial site)
- People who are able to understand the trial information and agree in writing to take part
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nabiel Mir, MD, University of Chicago
Phone: 1-855-702-8222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
feasibility of stopping LHRH agonist therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.